Literature DB >> 33792414

The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.

Thuy Nguyen1, Ulrike Muench2, Barbara Andraka-Christou3, Kosali Simon4,5, W David Bradford6, Joanne Spetz2.   

Abstract

This article examines the relationship between federal regulations, state scope-of-practice regulations on nurse practitioners (NPs), and buprenorphine prescribing patterns using pharmacy claims data from Optum's deidentified Clinformatics Data Mart between January 2015 and September 2018. The county-level proportion of patients filling prescriptions written by NPs was low even after the 2016 Comprehensive Addiction and Recovery Act (CARA), 2.7% in states that did not require physician oversight of NPs, and 1.1% in states that did. While analyses in rural counties showed higher rates of buprenorphine prescriptions written by NPs, rates were still considerably low: 3.7% in states with less restrictive regulations and 1.1% in other states. These results indicate that less restrictive scope-of-practice regulations are associated with greater NP prescribing following CARA. The small magnitude of the changes indicates that federal attempts to expand treatment access through CARA have been limited.

Entities:  

Keywords:  Comprehensive Addiction and Recovery Act; buprenorphine prescribing; nurse practitioners; scope-of-practice regulations

Mesh:

Substances:

Year:  2021        PMID: 33792414      PMCID: PMC8594929          DOI: 10.1177/10775587211004311

Source DB:  PubMed          Journal:  Med Care Res Rev        ISSN: 1077-5587            Impact factor:   3.929


  24 in total

1.  Applying lessons from task sharing in global mental health to the opioid crisis.

Authors:  Jessica F Magidson; Helen E Jack; Kristen S Regenauer; Bronwyn Myers
Journal:  J Consult Clin Psychol       Date:  2019-10

2.  Experiences and Attitudes of Primary Care Providers Under the First Year of ACA Coverage Expansion: Findings from the Kaiser Family Foundation/Commonwealth Fund 2015 National Survey of Primary Care Providers.

Authors: 
Journal:  Issue Brief (Commonw Fund)       Date:  2015-06

3.  Nurse Practitioner and Physician Assistant Waivers to Prescribe Buprenorphine and State Scope of Practice Restrictions.

Authors:  Joanne Spetz; Christopher Toretsky; Susan Chapman; Bethany Phoenix; Matthew Tierney
Journal:  JAMA       Date:  2019-04-09       Impact factor: 56.272

Review 4.  Variability in analgesic response to non-steroidal anti-inflammatory drugs.

Authors:  Katherine N Theken
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-10-25       Impact factor: 3.072

5.  Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.

Authors:  Christopher M Jones; Elinore F McCance-Katz
Journal:  Addiction       Date:  2018-10-15       Impact factor: 6.526

6.  Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration.

Authors:  Adam J Gordon; Greg Kavanagh; Margaret Krumm; Rajeev Ramgopal; Sanjay Paidisetty; Minu Aghevli; Francine Goodman; Jodie Trafton; Joseph Liberto
Journal:  Psychol Addict Behav       Date:  2011-06

7.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

8.  Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study.

Authors:  Douglas R Roehler; Gery P Guy; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2020-05-25       Impact factor: 4.492

9.  A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.

Authors:  Barbara Andraka-Christou; Matthew J Capone
Journal:  Int J Drug Policy       Date:  2018-01-08

10.  Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder.

Authors:  Thuy Nguyen; Barbara Andraka-Christou; Kosali Simon; W David Bradford
Journal:  JAMA Netw Open       Date:  2019-12-02
View more
  3 in total

1.  Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.

Authors:  Shailina Keshwani; Michael Maguire; Amie Goodin; Wei-Hsuan Lo-Ciganic; Debbie L Wilson; Juan M Hincapie-Castillo
Journal:  JAMA Health Forum       Date:  2022-06-24

2.  Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Joanne Spetz; Rachel Totaram; Matthew Golan; Olivia Randall-Kosich; Jordan Harrison; Spencer Calder; Stefan G Kertesz; Bradley D Stein
Journal:  J Subst Abuse Treat       Date:  2022-01-10

3.  Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.

Authors:  Barbara Andraka-Christou; Cory Page; Victoria Schoebel; Jessica Buche; Rebecca L Haffajee
Journal:  Addict Sci Clin Pract       Date:  2022-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.